FGFR2 and gastric cancer: EBV-associated GC and FGFR2-positive GC were consistent with significantly higher CLDN18.2-positive rates (46/64, 71.9% in EBV-associated GC; 68/154, 44.2% in FGFR2 positive GC; P < .05).